Search
Crotalus scutulatus antivenin
go.drugbank.com/drugs/DB13891ApprovedSpecimens with type A venom, which cause a different pattern of injury than other rattlesnakes, have been reported in southern California, Nevada, Utah, Arizona, Texas, and New Mexico [L2856].
GED-0507-34-Levo
go.drugbank.com/drugs/DB16109InvestigationalGED-0507-34-Levo is under investigation in clinical trial NCT02808390 (Efficacy and Safety Study of Ged-0507-34-levo for Treatment of UC).
Dysphagia
go.drugbank.com/conditions/DBCOND0010732Drugs: ChlorhexidineSynonyms: All grades Dysphagia, Dysphagia (all grades)Terevalefim
go.drugbank.com/drugs/DB16397InvestigationalTerevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Lumateperone
go.drugbank.com/drugs/DB06077ApprovedInvestigational[A189093] It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology
Categories: Dopamine D2 Receptor Agonists, Serotonin Receptor AntagonistsThiamylal
go.drugbank.com/drugs/DB01154ApprovedVet approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p919)
Neon
go.drugbank.com/drugs/DB11589ApprovedNeon is a chemical element with a chemical symbol Ne and atomic number 10. It is a noble gas that is colorless, odorless, inert and monatomic. It is the fifth most abundant chemical element in the universe by mass but a rare element on E...
Anthralin
go.drugbank.com/drugs/DB11157ApprovedAnthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. Adverse effects of anthralin include ...
U-0126
go.drugbank.com/drugs/DB17060ExperimentalU-0126 is a direct inhibitor of the mitogen-activated protein-kinase kinase family members, MEK-1 and MEK-2.[A253162]
Afizagabar
go.drugbank.com/drugs/DB21439InvestigationalAfizagabar is under investigation in clinical trial NCT02877615 (Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event).
Categories: GABA-A Receptor Antagonists